Vasculogenic Mimicry in Laryngeal Squamous Cell Carcinoma and Its Clinicopathological Significance_Journal of Biomedical Engineering

Authors：

 WUShiwu , YULan , ZHOULei , CHENGZenong , WANGDanna

Department of Pathology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, China;

Corresponding author：

WUShiwu, Email: honghongwuwu@sohu.com

Keywords：

laryngeal neoplasm; vasculogenic mimicry; microvessel density; galectin-3

DOI：

10.7507/1001-5515.20140163

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The present paper aims to investigate whether or not vasculogenic mimicry (VM) exists in laryngeal squamous cell carcinoma (LSCC), and to elucidate its relationship to microvessel density (MVD), galectin-3 (Gal-3) expressionb and clinicopathological factors of patients with LSCC. VM, score of MVD and expression of Gal-3 protein were detected by immunohistochemistry and histochemistry in 83 specimens of LSCC tissue and 20 specimens of normal laryngeal tissue. The positive rate of VM in normal laryngeal tissues was 0%, and was 33.7% in LSCC tissues. There was a significant difference between the two groups (P<0.01). VM or MVD was significantly related to differentiation, pTNM stages and lymph node metastasis of LSCC (P<0.05), but not to age, gender and tumor site (P>0.05). And there was a positive correlation between every two of VM, score of MVD, and Gal-3 protein (P<0.05). The results suggest that expression of Gal-3 protein may be related to the initiation, angiogenesis and VM formation in LSCC; And VM, angiogenesis and Gal-3 protein may be involved in the development, invasion and metastasis of LSCC.

Citation： WUShiwu, YULan, ZHOULei, CHENGZenong, WANGDanna. Vasculogenic Mimicry in Laryngeal Squamous Cell Carcinoma and Its Clinicopathological Significance. Journal of Biomedical Engineering, 2014, 31(4): 865-869. doi: 10.7507/1001-5515.20140163 Copy

1.	WANG W, LIN P, HAN C, et al. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2010, 29: 60.
2.	MANIOTIS A J, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752.
3.	YUE W Y, CHEN Z P. Does vasculogenic mimicry exist in astrocytoma?[J].J Histochem Cytochem, 2005, 53(8): 997-1002.
4.	NANGIA-MAKKER P, NAKAHARA S, HOGAN V, et al. Galectin-3 in apoptosis, a novel therapeutic target[J]. J Bioenerg Biomembr, 2007, 39(1): 79-84.
5.	O'DRISCOLL L, LINEHAN R, LIANG Y H, et al. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro[J]. Anticancer Res, 2002, 22(6A): 3117-3125.
6.	KUMADA T, TSUNEYAMA K, HATTA H, et al. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital[J]. Mod Pathol, 2004, 17(9): 1141-1149.
7.	武世伍,承泽农,俞岚,等. CD82/KAI1和HIF-1α在非小细胞肺癌中的表达及其与血管生成拟态的关系[J]. 中国肺癌杂志, 2011, 14(12): 918-925.
8.	承泽农,武世伍,俞岚,等.E-cad和Gal-3在喉鳞状细胞癌中的表达及其临床意义[J].中国组织化学与细胞化学杂志, 2012, 21(4): 406-410.
9.	SHIMAMURA T, SAKAMOTO M, INO Y, et al. Chinicopathological significance of galectin-3 expression in ductual adenocarcinoma of the pancreas[J]. Clin Cancer Res, 2002, 8(8): 2570-2575.
10.	MIYAZAKI J, HOKARI R, KATO S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes[J]. Oncol Rep, 2002, 9(6): 1307-1312.
11.	TSUBOI K, SHIMURA T, MASUDA N, et al. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis[J]. Anticancer Res, 2007, 27(4B): 2289-2296.
12.	IURISCI I, CUMASHI A, SHERMAN A A, et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis[J]. Anticancer Res, 2009, 29(1): 403-410.
13.	WANG Y, NANGIA-MAKKER P, TAIT L, et al. Regulation of prostate cancer progression by galectin[J]. Am J Pathol, 2009, 174(4): 1515-1523.
14.	WANG Y, NANGIA-MAKKER P, BALAN V, et al. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment[J]. Cell Death Dis, 2010, 1: e101.
15.	SAKAKI M, FUKUMORI T, FUKAWA T, et al. Clinical significance of galectin-3 in clear cell renal cell carcinoma[J]. J Med Invest, 2010, 57(1-2): 152-157.
16.	MATHIEU A, SAAL I, VUCKOVIC A, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung[J]. Mod Pahol, 2005, 18(9): 1264-1271.
17.	CANESIN G, GONZALEZ-PERAMATO P, PALOU J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome[J]. Tumour Biol, 2010, 31(4): 277-285.
18.	MATSUDA Y, YAMAGIWA Y, FUKUSHIMA K, et al. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma[J]. Hepatol Res, 2008, 38(11): 1098-1111.
19.	HTWE T T, KARIM N, WONG J, et al. Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis[J]. Singapore Med J, 2010, 51(11): 856-859.
20.	HAN C, SUN B, WANG W, et al. Overexpression of microtubule-associated protein-1 light chain 3 is associated with melanoma metastasis and vasculogenic mimicry[J]. Tohoku J Exp Med, 2011, 223(4): 243-241.
21.	HEYMAN L, LEROY-DUDAL J, FEMANDS J, et al. Mesothelial vitronectin stimulates migration of ovarian cancer cells[J]. Cell Biol Int, 2010, 34(5): 493-502.
22.	AHMADI S A, MOINFAR M, GOHARI MOQUADDAM K, et al. Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma[J]. Arch Iran Med, 2010, 13(6): 498-503.
23.	LI M, GU Y, ZHANG Z, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma[J]. Pathol Oncol Res, 2010, 16(2): 259-266.
24.	BASU G D, LIANG W S, STEPHAN D A, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cell[J]. Breast Cancer Res, 2006, 8(6): R69.
25.	LIU W B, XU G L, MA J L, et al. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma[J]. Tohoku J Exp Med, 2011, 224(1): 29-39.
26.	VARTANIAN A A, STEPANOVA E V, GUTOROV S L, et al. Prognostic significance of periodic acid-schiff-positive patterns in clear cell renal cell carcinoma[J]. Can J Urol, 2009, 16(4): 4726-4732.
27.	FOLBERG R, MANIOTIS A J. Vasculogenic mimicry[J]. APMIS, 2004, 112(7-8): 508-525.
28.	MINEO T C, AMBROGI V, BALDI A, et al. Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for ⅠB-ⅡA non-small cell lung cancer[J]. J Clin Pathol, 2004, 57(6): 591-597.
29.	MOURAD-ZEIDAN A A, MELNIKOVA V O, WANG H, et al. Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry[J]. Am J Pathol, 2008, 173(6): 1839-1852.

1. WANG W, LIN P, HAN C, et al. Vasculogenic mimicry contributes to lymph node metastasis of laryngeal squamous cell carcinoma[J]. J Exp Clin Cancer Res, 2010, 29: 60.
2. MANIOTIS A J, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739-752.
3. YUE W Y, CHEN Z P. Does vasculogenic mimicry exist in astrocytoma?[J].J Histochem Cytochem, 2005, 53(8): 997-1002.
4. NANGIA-MAKKER P, NAKAHARA S, HOGAN V, et al. Galectin-3 in apoptosis, a novel therapeutic target[J]. J Bioenerg Biomembr, 2007, 39(1): 79-84.
5. O'DRISCOLL L, LINEHAN R, LIANG Y H, et al. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro[J]. Anticancer Res, 2002, 22(6A): 3117-3125.
6. KUMADA T, TSUNEYAMA K, HATTA H, et al. Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital[J]. Mod Pathol, 2004, 17(9): 1141-1149.
7. 武世伍,承泽农,俞岚,等. CD82/KAI1和HIF-1α在非小细胞肺癌中的表达及其与血管生成拟态的关系[J]. 中国肺癌杂志, 2011, 14(12): 918-925.
8. 承泽农,武世伍,俞岚,等.E-cad和Gal-3在喉鳞状细胞癌中的表达及其临床意义[J].中国组织化学与细胞化学杂志, 2012, 21(4): 406-410.
9. SHIMAMURA T, SAKAMOTO M, INO Y, et al. Chinicopathological significance of galectin-3 expression in ductual adenocarcinoma of the pancreas[J]. Clin Cancer Res, 2002, 8(8): 2570-2575.
10. MIYAZAKI J, HOKARI R, KATO S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes[J]. Oncol Rep, 2002, 9(6): 1307-1312.
11. TSUBOI K, SHIMURA T, MASUDA N, et al. Galectin-3 expression in colorectal cancer: relation to invasion and metastasis[J]. Anticancer Res, 2007, 27(4B): 2289-2296.
12. IURISCI I, CUMASHI A, SHERMAN A A, et al. Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis[J]. Anticancer Res, 2009, 29(1): 403-410.
13. WANG Y, NANGIA-MAKKER P, TAIT L, et al. Regulation of prostate cancer progression by galectin[J]. Am J Pathol, 2009, 174(4): 1515-1523.
14. WANG Y, NANGIA-MAKKER P, BALAN V, et al. Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment[J]. Cell Death Dis, 2010, 1: e101.
15. SAKAKI M, FUKUMORI T, FUKAWA T, et al. Clinical significance of galectin-3 in clear cell renal cell carcinoma[J]. J Med Invest, 2010, 57(1-2): 152-157.
16. MATHIEU A, SAAL I, VUCKOVIC A, et al. Nuclear galectin-3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung[J]. Mod Pahol, 2005, 18(9): 1264-1271.
17. CANESIN G, GONZALEZ-PERAMATO P, PALOU J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome[J]. Tumour Biol, 2010, 31(4): 277-285.
18. MATSUDA Y, YAMAGIWA Y, FUKUSHIMA K, et al. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma[J]. Hepatol Res, 2008, 38(11): 1098-1111.
19. HTWE T T, KARIM N, WONG J, et al. Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis[J]. Singapore Med J, 2010, 51(11): 856-859.
20. HAN C, SUN B, WANG W, et al. Overexpression of microtubule-associated protein-1 light chain 3 is associated with melanoma metastasis and vasculogenic mimicry[J]. Tohoku J Exp Med, 2011, 223(4): 243-241.
21. HEYMAN L, LEROY-DUDAL J, FEMANDS J, et al. Mesothelial vitronectin stimulates migration of ovarian cancer cells[J]. Cell Biol Int, 2010, 34(5): 493-502.
22. AHMADI S A, MOINFAR M, GOHARI MOQUADDAM K, et al. Practical application of angiogenesis and vasculogenic mimicry in prostatic adenocarcinoma[J]. Arch Iran Med, 2010, 13(6): 498-503.
23. LI M, GU Y, ZHANG Z, et al. Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma[J]. Pathol Oncol Res, 2010, 16(2): 259-266.
24. BASU G D, LIANG W S, STEPHAN D A, et al. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cell[J]. Breast Cancer Res, 2006, 8(6): R69.
25. LIU W B, XU G L, MA J L, et al. Osteopontin as a key mediator for vasculogenic mimicry in hepatocellular carcinoma[J]. Tohoku J Exp Med, 2011, 224(1): 29-39.
26. VARTANIAN A A, STEPANOVA E V, GUTOROV S L, et al. Prognostic significance of periodic acid-schiff-positive patterns in clear cell renal cell carcinoma[J]. Can J Urol, 2009, 16(4): 4726-4732.
27. FOLBERG R, MANIOTIS A J. Vasculogenic mimicry[J]. APMIS, 2004, 112(7-8): 508-525.
28. MINEO T C, AMBROGI V, BALDI A, et al. Prognostic impact of VEGF, CD31, CD34 and CD105 expression and tumor vessel invasion after radical surgery for ⅠB-ⅡA non-small cell lung cancer[J]. J Clin Pathol, 2004, 57(6): 591-597.
29. MOURAD-ZEIDAN A A, MELNIKOVA V O, WANG H, et al. Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry[J]. Am J Pathol, 2008, 173(6): 1839-1852.

Journal of Biomedical Engineering

Vasculogenic Mimicry in Laryngeal Squamous Cell Carcinoma and Its Clinicopathological Significance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content